Core Viewpoint - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., has successfully passed the consistency evaluation for the generic drug Tramadol Hydrochloride Tablets (50mg) [1][2]. Group 1: Drug Approval Details - The drug name is Tramadol Hydrochloride Tablets, in tablet form, with a specification of 50mg [1]. - The approval notice number is 2026B00624, and the drug is classified as a chemical drug [1]. - The approval includes changes to the prescription, manufacturing process, production batch, quality standards, and shelf life [1]. Group 2: Market Context - The original drug has not been marketed in China, but there are currently eight generic versions approved, with three having passed the consistency evaluation [2]. - Beijing Huasu is the third domestic company to receive approval for this drug's consistency evaluation [2]. Group 3: Financial Investment - The total research and development investment for the consistency evaluation project of Tramadol Hydrochloride Tablets has reached approximately 5.9 million yuan [3]. Group 4: Impact on Company Performance - The approval is expected to enhance the market competitiveness of the drug and positively impact the company's operating performance [5]. - The company emphasizes the importance of drug research and development, maintaining strict quality control throughout the drug development, manufacturing, and sales processes [5].

Core Insights - The 9th Zhongguancun International Frontier Technology Competition recently held its semifinals in the new materials sector, showcasing innovative projects such as "Integrated Optical Frequency Comb" and "High-end Quantum Dot Display for Vehicles" [1] Group 1: New Materials Innovations - The "Integrated Optical Frequency Comb" project by Qiming Photonics Technology is notable for its ability to output 34 or more evenly spaced wavelengths through a single chip, addressing bandwidth and power consumption challenges in optical interconnect technology [1][2] - The project utilizes a modified "optical frequency comb" technology that previously required expensive equipment, achieving chip-level integration that simplifies control logic and reduces power consumption and costs [2] - Other top projects include "Topological Soft Gel for Winter Protection," "Advanced Tactile Sensors for Robots," and a platform for "Extracellular Vesicles from Stem Cells," indicating significant advancements in various fields such as smart equipment, biomedical applications, and advanced displays [3] Group 2: Competition Structure and Evaluation - The competition features a jury of experts from academia, investment, and industry who evaluate projects based on technological advancement and market potential, providing professional advice for innovation and long-term development [6] - The 9th Frontier Competition is organized by the Beijing Municipal Science and Technology Commission and the Zhongguancun Management Committee, with the semifinals scheduled for March 2026 and the finals during the Zhongguancun Forum annual meeting [6]

Group 1 - The core point of the article highlights the recent performance of Zhongguancun (000931), which closed at 5.3 yuan on February 9, 2026, with a 1.92% increase and a turnover rate of 2.12% [1] - The stock experienced a net inflow of main funds amounting to 11.89 million yuan, representing 14.15% of the total transaction amount, while retail investors saw a net outflow of 9.45 million yuan, accounting for 11.23% of the total [1] - For the first three quarters of 2025, Zhongguancun reported a main revenue of 1.882 billion yuan, a year-on-year decrease of 2.46%, and a net profit attributable to shareholders of 49.49 million yuan, down 4.14% year-on-year [1] Group 2 - The company’s main business segments include biopharmaceuticals and health products, elderly medical services, commercial concrete, and other businesses [1] - The biopharmaceutical and health products segment involves the research, manufacturing, and sales of various pharmaceutical forms, including chemical drugs, traditional Chinese medicine, and medical devices [1] - The elderly medical services segment encompasses centralized elderly care, home care services, health management, and internet hospital services [1]

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

Core Viewpoint - Zhongguancun (000931.SZ) announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its drug "Tramadol Hydrochloride Tablets" (specification: 50mg), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval notification number for the drug is 2026B00624 [1] - The drug is recognized for its quality and efficacy consistency, which is crucial for generic medications [1]

Core Viewpoint - Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of Zhongguancun (000931.SZ), has received approval from the National Medical Products Administration for its drug "Tramadol Hydrochloride Tablets" (specification: 50mg), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval signifies a key milestone for Beijing Huasu in the pharmaceutical market [1] - The drug "Tramadol Hydrochloride Tablets" is now positioned to compete effectively in the generic drug sector [1] - This development may enhance the company's revenue potential and market share in the pain management segment [1]

Core Viewpoint - Beijing Huasu Pharmaceutical, a subsidiary of Zhongguancun, has received notification from the National Medical Products Administration that its product "Tramadol Hydrochloride Tablets" (50mg) has passed the consistency evaluation for generic drug quality and efficacy [1] Group 1: Company Developments - Beijing Huasu is the fourth company to pass the consistency evaluation, joining three other companies that have already received approval [1] - The project has incurred a total research and development cost of approximately 5.9 million yuan [1] Group 2: Market Impact - The successful evaluation is expected to enhance the competitiveness of the drug and positively impact the company's performance [1] - However, drug sales are influenced by various factors, leading to inherent uncertainties [1]

关于下属公司北京华素盐酸曲马多片通过一致性评价的公告 共 3 页 证券代码：000931 证券简称：中关村 公告编号：2026-017 北京中关村科技发展（控股）股份有限公司 关于下属公司北京华素盐酸曲马多片通过一致性评价的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）于 2025 年 1 月披露《关于下属公司北京华素盐酸曲马多片一致性评价申报收到国家药品 监督管理局<受理通知书>的公告》（公告编号：2025-006）。 近日，公司下属公司北京华素制药股份有限公司（以下简称：北京华素） 收到国家药品监督管理局核准签发的《药品补充申请批准通知书》（通知书编 号：2026B00624），获悉，北京华素生产的"盐酸曲马多片"（规格：50mg） 通过了仿制药质量和疗效一致性评价，具体情况如下： 一、批件主要内容 通知书编号：2026B00624 药品名称：盐酸曲马多片 剂型：片剂 规格：50mg 注册分类：化学药品 受理号：CYHB2550038 上市许可持有人、生产企业：北京华素制药股份有限公司 包装规 ...

Core Viewpoint - The construction of the Zhongguancun Digital Economy Headquarters Park is progressing well, with the main structure completed ahead of schedule, showcasing innovative construction techniques and strong team commitment [1][3]. Group 1: Project Overview - The total construction area of the Zhongguancun Digital Economy Headquarters Park is 407,900 square meters, making it the largest ongoing TOD industrial park in Haidian [1]. - The project is located near the Qinghe transportation hub and is expected to be completed by May 2027, integrating industrial offices, vibrant commercial spaces, high-end hotels, and serviced apartments [3]. Group 2: Construction Challenges and Solutions - The project faced significant challenges, including uneven groundwater levels and complex geological conditions, which were addressed through innovative dewatering methods [1]. - A combination of "vacuum pump lightweight well points + drainage wells" was successfully implemented to tackle the underground water issues, facilitating subsequent construction [1]. Group 3: Technological Innovations - A 350-meter long prefabricated steel bridge was constructed to enhance transportation efficiency, increasing horizontal transport capacity by 40% and concrete pouring volume by 85% [2]. - The use of intelligent construction robots has significantly improved efficiency, with construction speed increased by 2-3 times compared to manual labor [2]. Group 4: Team Commitment - The construction team demonstrated strong dedication, with many workers postponing their return home for the New Year to meet project deadlines, reflecting their sense of responsibility [3]. - At peak construction, over 2,000 workers were on-site, with a commitment to continue working through the holiday period to ensure project completion [3].

本报讯 （记者 边磊） 近日，毗邻清河交通枢纽的中关村数字经济总部园主体结构全面封顶。这座总建 筑面积达40.79万平方米的海淀最大在施TOD产业园区，仅用3个月就实现从"正负零"到高楼林立的跨 越，彰显了北京建工六建的铁军风采，更为中关村数字经济发展注入新动能。 （来源：劳动午报） 转自：劳动午报 据了解，作为承载区域数字经济发展愿景的重点项目，中关村数字经济总部园预计2027年5月完工，将 打造集产业办公、活力商业、高端酒店、服务式公寓于一体的TOD创新产城融合体。未来，该项目将 强化与小米科技园、上地信息产业基地等创新载体的协同，聚焦人工智能、大信息、大健康等核心产 业，聚集行业领军企业，助力海淀打造数字经济引领区和人工智能创新策源地。 本报记者 于佳 摄 ...